# Lumvoa™ (veligrotug) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/veligrotug

> The FDA approved Lumvoa™ (veligrotug), sponsored by Viridian Therapeutics, Inc.\DE (VRDN), on June 26, 2026 for thyroid eye disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Lumvoa™ (veligrotug) FDA approved?

Yes. The FDA approved Lumvoa™ (veligrotug), sponsored by Viridian Therapeutics, Inc.\DE (VRDN), on June 26, 2026 for thyroid eye disease. SEC Form 8-K: "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." [Calendar and source filings](https://sec-api.dev/pdufa/veligrotug)

Source: SEC Form 8-K, accession 0001193125-26-286273, https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/veligrotug#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lumvoa™ (veligrotug) |
| Codes | ZB001, VRDN-001 |
| Sponsor | Viridian Therapeutics, Inc.\DE (VRDN) https://sec-api.dev/companies/vrdn/catalysts |
| Indications | [thyroid eye disease](https://sec-api.dev/indications/thyroid-eye-disease), ted in june 2026, ted regardless of activity or duration, chronic thyroid eye disease, [chronic ted](https://sec-api.dev/indications/chronic-ted) |
| Modality |  |
| FDA designations | breakthrough, priority review |

## Timeline

### May 2022: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-12, last confirmed 2025-08-06.
- SEC Form 10-Q (accession 0001590750-25-000012): "In May 2022, the Company paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000012/vrdn-20250630.htm
- SEC Form 10-Q (accession 0001590750-25-000008): "In May 2022, the Company paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000008/vrdn-20250331.htm
- SEC Form 10-K (accession 0001590750-25-000004): "In May 2022, we paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm
- SEC Form 10-K (accession 0001590750-25-000004): "In May 2022, the Company paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm
- SEC Form 10-Q (accession 0001590750-24-000023): "In May 2022, the Company paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." https://www.sec.gov/Archives/edgar/data/1590750/000159075024000023/vrdn-20240930.htm

### Dec 2022: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-12, last confirmed 2025-08-06.
- SEC Form 10-Q (accession 0001590750-25-000012): "In December 2022, the Company recorded $10.0 million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, which was paid in January 2023." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000012/vrdn-20250630.htm
- SEC Form 10-Q (accession 0001590750-25-000008): "In December 2022, the Company recorded $10.0 million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, which was paid in January 2023." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000008/vrdn-20250331.htm
- SEC Form 10-K (accession 0001590750-25-000004): "In December 2022, the Company recorded $10.0 million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, amount which was paid in January 2023." https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm
- SEC Form 10-Q (accession 0001590750-24-000023): "In December 2022, the Company recorded $10.0 million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, amount which was paid in January 2023." https://www.sec.gov/Archives/edgar/data/1590750/000159075024000023/vrdn-20240930.htm

### late 2024: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001590750-24-000023): "We completed enrollment of THRIVE-2 in July 2024, and expect to announce topline data for this study by the end of 2024." https://www.sec.gov/Archives/edgar/data/1590750/000159075024000023/vrdn-20240930.htm

### December 16, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: chronic TED.
- First seen 2024-11-12, last confirmed 2024-12-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-279021): "WALTHAM, Mass., December 16, 2024  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED)." https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-255130): "THRIVE-2 Topline Data Readout on Track for December 2024: THRIVE-2 is a global phase 3 clinical trial assessing the efficacy and safety of veligrotug after five infusions in patients with chronic TED." https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553dex991.htm
- SEC Form 10-Q (accession 0001590750-24-000023): "These THRIVE topline results may also not be reflective of our phase 3 THRIVE-2 trial, for which topline results are expected by year end 2024." https://www.sec.gov/Archives/edgar/data/1590750/000159075024000023/vrdn-20240930.htm

### May 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-14T10:20:01.161Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." https://clinicaltrials.gov/study/NCT06384547

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-12, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001590750-25-000020): "•the timing or likelihood of regulatory filings and approvals, including the anticipated filing and approval of the biologics license application ("BLA") by FDA for veligrotug and submission of a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") in the first quarter of 2026, as well as our expectation that Breakthrough Therapy Designation may support eligibility for and potential receipt of Priority Review of our BLA, and our expectation to seek an accelerated approval pathway and special designations for our product candidates for various diseases;" https://www.sec.gov/Archives/edgar/data/1590750/000159075025000020/vrdn-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-037586): "Viridians President and CEO. The veligrotug BLA submission is on track for 2H 2025 and our early commercial preparations are underway." https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/d865236dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-255130): "Viridians expectation that its data package will support a BLA submission for veligrotug in the second half of 2025, pending data" https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553dex991.htm

### June 26, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: thyroid eye disease.
- First seen 2026-06-29, last confirmed 2026-11-04.
- SEC Form 8-K (accession 0001193125-26-286273): "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm
- SEC Form 8-K (accession 0001193125-26-286273): "On June 26, 2026, the Company announced that the FDA has approved Lumvoa™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration." https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-286273): "WALTHAM, Mass. - (BUSINESS WIRE) - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED)." https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211dex991.htm
- SEC Form 10-Q (accession 0001590750-26-000022): "Following the FDA approval of veligrotug in June 2026, the Company received a $75.0 million milestone payment pursuant to the DRI Purchase and Sale Agreement." https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/vrdn-20260930.htm
- SEC Form 10-Q (accession 0001590750-26-000022): "In June 2026, we received marketing approval from the FDA for veligrotug in the United States." https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/vrdn-20260930.htm
- SEC Form 10-Q (accession 0001590750-26-000018): "Following the FDA approval of veligrotug in June 2026, the Company became entitled to receive a $75.0 million milestone payment pursuant to the DRI Purchase and Sale Agreement." https://www.sec.gov/Archives/edgar/data/1590750/000159075026000018/vrdn-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336691): "The U.S. Food and Drug Administration (FDA) approved Lumvoa for the treatment of TED on June 26, 2026." https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-106699): "LUMVOA™ (veligrotug-vvze) was approved by the FDA for the treatment of TED in June 2026." https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/tm2624937d1_ex99-2.htm

### June 26, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336691): "- Lumvoa (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -" https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm
- SEC Form 8-K (accession 0001193125-26-286273): "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm

### June 30, 2026: topline data readout

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2026-03-30, last confirmed 2026-03-30.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-130433): "FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2" https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex992.htm

### June 30, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2026-02-26, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205010): "- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -" https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205010): "Veligrotug: PDUFA target action date of June 30, 2026; ready to launch" https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205099): "Veligrotug on Track with a PDUFA Target Action Date of June 30, 2026" https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205099): "Veligrotug PDUFA target date of June 30, 2026 Veligrotug in Active TED" https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-130433): "Veligrotug on Track with a PDUFA Target Action Date of June 30, 2026" https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-130433): "FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2" https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073391): "- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -" https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073391): ""With the veligrotug BLA filing under Priority Review and a PDUFA target date of June 30, 2026, we are well-prepared for our potential first commercial launch, a significant milestone for the company and for patients with TED." https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073391): "Veligrotug: U.S. Biologics License Application (BLA) Priority Review ongoing; Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026" https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073391): "U.S. Food and Drug Administration (FDA) Priority Review of veligrotug BLA for TED is ongoing with a PDUFA target action date of June 30, 2026." https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm
- SEC Form 10-Q (accession 0001590750-26-000012): "We submitted a BLA for veligrotug to the FDA in October 2025, which was accepted for filing and granted Priority Review in December 2025 with a Prescription Drug User Free Act ("PDUFA") target action date of June 30, 2026." https://www.sec.gov/Archives/edgar/data/1590750/000159075026000012/vrdn-20260331.htm
- SEC Form 10-Q (accession 0001590750-26-000012): "Delays at the FDA as a result of these or other factors could impact the FDA's ability to act on our BLA submission for veligrotug by the PDUFA target action date of June 30, 2026, or any of our other regulatory submissions." https://www.sec.gov/Archives/edgar/data/1590750/000159075026000012/vrdn-20260331.htm

### August 13, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Thyroid Eye Disease.
- First seen 2026-11-14T10:20:01.161Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." https://clinicaltrials.gov/study/NCT06384547?tab=results

### Q1 2027: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-05-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205099): "Viridian's expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug and the anticipated submission of a BLA for elegrobart in Q1 2027;" https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm

### 2H 2027: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2024-12-16, last confirmed 2024-12-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-279021): "- Strong cash position of $753 million as of September 30, 2024; provides cash runway into the second half of 2027 through the anticipated commercial launch of veligrotug, topline results and BLA submission for subcutaneous VRDN-003, and multiple FcRn inhibitor clinical catalysts -" https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm

## Same indication

- [Batoclimab](https://sec-api.dev/pdufa/batoclimab) (IMVT)
- [Elegrobart](https://sec-api.dev/pdufa/elegrobart) (VRDN)

Calendar months: [June 2026](https://sec-api.dev/fda-calendar/2026-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/veligrotug.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lumvoa™ (veligrotug) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/veligrotug

```bibtex
@misc{secapidev_pdufa_veligrotug_20261116,
  title        = {Lumvoa™ (veligrotug) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/veligrotug}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_veligrotug_20261116","title":"Lumvoa™ (veligrotug) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/veligrotug","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
